

## IMATINIB RESISTANCE -MUTATION ANALYSIS

IMATINIB RESISTANCE - MUTATION ANALYSIS	
(PCR, sequencing)	
Mutations	Detected / Not Detected
Mutations detected	Free Text

### Note:

1. Mutations below the detection limits of the assay may not be detected.
2. This test detects mutations in the ABL kinase domain of the BCR-ABL transcript and predicts resistance to Imatinib based on these mutations.
3. This is an in-house developed test for Research purposes only.
4. All results to be interpreted in context of clinical findings, and other laboratory data.

### Comments

Imatinib is a Tyrosine Kinase Inhibitor (TKI) capable of inducing durable cytogenetic and hematologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develops functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage. Over a hundred different mutations are known in the tyrosine kinase domain. The most common mutation is the T315I where threonine changes to Isoleucine.